Rita Nanda to High-Throughput Nucleotide Sequencing
This is a "connection" page, showing publications Rita Nanda has written about High-Throughput Nucleotide Sequencing.
Connection Strength
0.040
-
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. J Clin Oncol. 2022 02 01; 40(4):345-355.
Score: 0.040